Nanoformulated long-acting cabotegravir prodrugs are shown to be capable of extending the native drug’s antiretroviral activity, biodistribution and pharmacokinetics for up to 12 months in mice and rhesus macaques.
- Tanmay A. Kulkarni
- Aditya N. Bade
- Howard E. Gendelman